RNL Bio, a South Korean adult stem cell therapy company, developed a method to take one's own stem cells from fat tissue and make identical copies that have no genetic modifications and no cancer risks so that high doses of stem cells can be administered back into the body. The stem cells that come from fat tissue can easily form new tissues. Given that characteristic, the stem cells have the capacity to treat any tissue degenerative disease which includes, Parkinson's Disease, Spinal Cord Injury, Renal Failure, among many. When Cullison heard of the treatment, he sent a small fat sample to RNL Bio, where the cells would be manufactured under the strictest safety and quality conditions.
A week after his injection, Cullison began to see small improvements and after two weeks, he no longer needed his cane to walk. He noticed that his joints were feeling better, his vision was improving to the point that his glasses were outdated, his eyes were getting bluer (eye pigmentation is often an indicator of good health) and his legs were getting stronger. "This is major improvement and it's only been 2 weeks! Six months from now, I'll be doing back-flips!" Only three weeks post treatment, Cullison reported that he was no longer taking any medication and back to painting his pictures.
President and CEO of RNL Bio, Dr.
About RNL Bio
RNL Bio is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis. RNL is a publically traded company on the Korean Stock Exchange (Code 003190) and plans to expand its operations throughout the world. For questions regarding the press conference or receiving stem cell therapy, please contact,
SOURCE RNL Bio